Cited by 1,340Sirtuins and Resveratrol in MedicineMetabolism, Diabetes, and CancerAdipose Tissue and Metabolism

Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice

Open access
Yoshino, Jun, Mills, Kathryn F., Yoon, Myeong Jin, Imai, Shin-ichiro·2011·Cell Metabolism

Abstract

Type 2 diabetes (T2D) has become epidemic in our modern lifestyle, likely due to calorie-rich diets overwhelming our adaptive metabolic pathways. One such pathway is mediated by nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in mammalian NAD(+) biosynthesis, and the NAD(+)-dependent protein deacetylase SIRT1. Here, we show that NAMPT-mediated NAD(+) biosynthesis is severely compromised in metabolic organs by high-fat diet (HFD). Strikingly, nicotinamide mononucleotide (NMN), a product of the NAMPT reaction and a key NAD(+) intermediate, ameliorates glucose intolerance by restoring NAD(+) levels in HFD-induced T2D mice. NMN also enhances hepatic insulin sensitivity and restores gene expression related to oxidative stress, inflammatory response, and circadian rhythm, partly through SIRT1 activation. Furthermore, NAD(+) and NAMPT levels show significant decreases in multiple organs during aging, and NMN improves glucose intolerance and lipid profiles in age-induced T2D mice. These findings provide critical insights into a potential nutriceutical intervention against diet- and age-induced T2D.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2011.08.014

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Under stress conditions, NAD+ biosynthesis and NAD+ levels decrease while the activity of NAD-consuming enzymes increases.

    “In stress conditions, NAD+ biosynthesis and levels decrease as well as the activity of consuming enzymes rises.”

    From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [13]

    The Results report that inflammatory and oxidative-stress treatments reduced NAMPT and NAD+ levels in primary hepatocytes, and the Discussion links reduced NAD+ biosynthesis to inflammation or oxidative stress. The paper does not report a rise in NAD-consuming enzyme activity under those conditions; its Results instead suggest that SIRT1 activity is suppressed by a high-fat diet. No page numbers are available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • NMN and NR protect against diabetes, Alzheimer disease, endothelial dysfunction, and inflammation.

    “NMN and NR demonstrated protect against diabetes, Alzheimer disease, endothelial dysfunction, and inflammation.”

    From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [13]

    The Results and Discussion (page unavailable) report that NMN improved glucose tolerance in diet- and age-induced diabetic mice and reversed inflammatory-response gene-expression changes. They do not show that NR protects against these conditions; NR was measured after NMN administration, not tested as a treatment. The paper also does not establish protection against Alzheimer disease or endothelial dysfunction, or demonstrate prevention of inflammation as a clinical condition. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • NAD+ synthesis can occur from tryptophan and vitamin B3, and NR and NMN also promote NAD+ synthesis.

    “NAD+ synthesis can occur from tryptophan and vitamin B3 (niacin and nicotinamide). Later, the intermediates NR and NMN have also been identified to promote NAD+ synthesis [13, 55].”

    From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [13]

    The Results section (page not supplied) shows that administered NMN was converted to NAD+ and enhanced NAD+ biosynthesis. It reports an increase in NR after NMN administration, but does not establish that NR itself promotes NAD+ synthesis. The citation is attached to the sentence about NR and NMN, not the preceding sentence about tryptophan and vitamin B3. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • NAMPT protein and NAD+ levels decrease significantly in white adipose tissue and skeletal muscle of old mice, affecting NAD-dependent enzymes such as sirtuins.

    “The NAMPT (nicotinamide phosphoribosyltransferase) protein and NAD+ levels decreased significantly in organs, such as white adipose tissue and skeletal muscle in old mice [13] affecting the activity of NAD+ -dependent enzymes such as sirtuins [15, 98].”

    From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [13]

    The Results section on age-induced diabetes reports significant NAD+ decreases in white adipose tissue and skeletal muscle of old mice and says NAMPT protein levels also decreased in those tissues. It does not state that the NAMPT decreases were statistically significant. The sirtuin-activity clause is attached to different citations, so it is not assessed here; no page number is available in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • NMN has been proposed as a nutraceutical to prevent age-related physiological decline and has been shown to improve diabetes and Alzheimer disease, enhance aerobic capacity, and exert cardio- and vasoprotective, anti-inflammatory, antioxidant, endothelial-protective, heart failure-protective, and ischemia/reperfusion-protective effects.

    “Proposed as a nutraceutical to prevent age-related physiological decline [1••, 91], NMN has shown to improve diabetes [13, 20, 38] and Alzheimer’s disease [22, 23], enhance aerobic capacity [92], and exhibit cardio- and vasoprotective actions. It inhibits inflammation and decreases oxidative stress, preventing arterial and endothelial dysfunction [32, 93], and protecting against heart failure [94]”

    From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [13]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Imai, Shin-ichiro
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2011-10
Volume
14
Issue
4
Pages
528-536
ISSN
1550-4131 (ISSN-L)
OpenAlex
W2038011036
Cited by
1,340
References
27
Citations by year
2026: 65 · 2025: 98 · 2024: 129 · 2023: 127 · 2022: 145 · 2021: 133 · 2020: 98 · 2019: 111 · 2018: 88 · 2017: 82 · 2016: 76 · 2015: 55 · 2014: 61 · 2013: 51 · 2012: 19
FWCI
20.43
Type
journal article
Language
en
Open access
Locations
  • Cell Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (AG02150)
  • Ellison Medical Foundation
  • Longer Life Foundation
  • Japan Research Foundation for Clinical Pharmacology
  • Manpei Suzuki Diabetes Foundation
  • Kanae Foundation for the Promotion of Medical Science
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
nicotinamide mononucleotide, NAD biosynthesis, visfatin, SIRT1, type 2 diabetes, high-fat diet, aging, impaired glucose tolerance, hepatic insulin sensitivity, oxidative stress, inflammation, circadian rhythm
MeSH terms
Aging, Animals, Circadian Rhythm, Diabetes Mellitus, Type 2, Disease Models, Animal, Gene Expression Regulation, Glucose, Hypoglycemic Agents, Insulin, NAD, Nicotinamide Mononucleotide, Cytokines, Oxidative Stress, Lipid Metabolism, Mice, Nicotinamide Phosphoribosyltransferase, Sirtuin 1, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review